2022
DOI: 10.1161/circ.146.suppl_1.13642
|View full text |Cite
|
Sign up to set email alerts
|

Abstract 13642: Post-Operative Bleeding Risk in TAVR Patients With Atrial Fibrillation

Abstract: Introduction: Antithrombotic medications are the subject of multiple transcatheter aortic valve replacement (TAVR) randomized control trials. Pragmatically, decisions are complicated by conditions such as atrial fibrillation (AF) that also require lifetime anticoagulation. Our study examines antithrombotic medications in a real-world cohort to identify risk factors for bleeding by 1-year post-TAVR. Methods: This retrospective study includes 844 patients… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles